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ABSTRACT:
Heat shock proteins (Hsp) are increasingly employed as therapeutic targets 
in oncology. We have shown that Hsp32, also known as heme oxygenase-1 (HO-
1), serves as survival factor and potential target in Ph+ chronic myeloid leukemia. 
We here report that primary cells and cell lines derived from patients with acute 
lymphoblastic leukemia (ALL) express Hsp32 mRNA and the Hsp32  protein in a 
constitutive manner. Highly enriched CD34+/CD38− ALL stem cells also expressed 
Hsp32. Two Hsp32-targeting drugs, pegylated zinc protoporphyrine (PEG-ZnPP) and 
styrene maleic acid-micelle-encapsulated ZnPP (SMA-ZnPP), induced apoptosis and 
growth arrest in the BCR/ABL1+ cell lines, in Ph− lymphoblastic cell lines and in 
primary Ph+ and Ph− ALL cells. The effects of PEG-ZnPP and SMA-ZnPP on growth of 
leukemic cells were dose-dependent. In Ph+ ALL, major growth-inhibitory effects of 
the Hsp32-targeting drugs were observed in imatinib-sensitive and imatinib-resistant 
cells. Hsp32-targeting drugs were found to synergize with imatinib, nilotinib, and 
bendamustine in producing growth inhibition and apoptosis in Ph+ ALL cells. A siRNA 
against Hsp32 was found to inhibit growth and survival of ALL cells and to synergize 
with imatinib in suppressing the growth of ALL cells. In conclusion, Hsp32 is an 
essential survival factor and potential new target in ALL.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is a life-
threatening neoplasm characterized by uncontrolled 
growth and leukemic expansion of immature lymphoblastic 
progenitor cells [1-4]. The prognosis and outcome in ALL 
depend on age, molecular defects and response to therapy 
[1-6]. In about 30% of all adult patients, leukemic cells 
display the Philadelphia chromosome (Ph) and the related 
fusion gene, BCR/ABL1 [1-6]. In the ´pre-imatinib-era´, 
these patients had an extremely poor prognosis compared 
to patients with Ph- ALL [5,6]. Since then the prognosis 
of patients with BCR/ABL1+ ALL has improved, which 
is largely attributable to the effects of novel BCR/ABL1-
targeting drugs [7-12]. In fact, the BCR/ABL1 tyrosine 
kinase inhibitor (TKI) imatinib is effective in most patients 
with newly diagnosed Ph+ ALL, and sometimes even in 
patients with chemotherapy-resistant or relapsed Ph+ ALL, 
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especially when applied in combination with conventional 
chemotherapy [7-13]. Second- and third generation BCR/
ABL1 blockers are also effective in patients with Ph+ ALL 
[14].
However, not all patients with Ph+ ALL respond 
to standard treatment and TKI. Therefore, depending on 
age, risk factors, and availability of a donor, stem cell 
transplantation (SCT) is recommended for patients with 
drug-resistant and high risk ALL [15-18]. In these patients, 
the overall treatment plan often combines chemotherapy, 
SCT and BCR/ABL1-targeting drugs [17]. However, 
despite SCT and the availability of novel targeted drugs, 
not all patients with Ph+ ALL can be cured. Therefore, 
current research focuses on identifying new targets and 
drugs that can be employed in these patients and may 
improve outcome and survival in ALL the future.
One class of interesting new targets in oncology 
are heat shock proteins (Hsp). These proteins often act 
as survival factors and are expressed in neoplastic cells 
in a constitutive manner [19]. Heat shock protein 32 
(Hsp32), also known as heme oxygenase-1 (HO-1), is a 
stress-related cytoprotective molecule that is expressed in 
normal and neoplastic cells, including myeloid leukemias 
[20-28]. In neoplastic cells, Hsp32 is considered to play 
a major role as an essential survival factor [22-29]. We 
have recently shown that Hsp32 (HO-1) is expressed in 
leukemic cells in Ph+ chronic myeloid leukemia (CML) 
and that Hsp32-targeting drugs produce growth arrest and 
apoptosis in leukemic cells [28,29].
In the present study, we show that Hsp32 is 
expressed in leukemic cells in Ph+ and Ph− ALL, and 
that pharmacologic inhibitors of Hsp32 suppress the 
growth of imatinib-sensitive as well as imatinib-resistant 
ALL cells. Moreover, we show that drug combinations 
consisting of Hsp32 inhibitors and either BCR/ABL1 TKI 
or bendamustin, can produce synergistic growth-inhibitory 
effects in imatinib-resistant ALL cells.
RESULTS
ALL cells express Hsp32 mRNA and the Hsp32 
protein
As assessed by qPCR, primary ALL cells as well 
as the ALL cell lines tested were found to express Hsp32 
mRNA (Figure 1A, Tables 1 and 2). Hsp32 transcripts 
were present in Ph+ ALL cells as well as in Ph− ALL cells 
(Figure 1A). Hemin was found to promote expression 
of Hsp23 mRNA in all ALL samples tested (Figure 
1A). We were also able to show that ALL cells display 
the Hsp32 protein. Expression of the Hsp32 protein was 
demonstrable by immunocytochemistry (Figure 1B) as 
well as by Western blotting (Figure 1C), and hemin was 
found to upregulate expression of the Hsp32 protein in 
ALL cells (Figure 1B and 1C). Since leukemic stem 
cells are considered a major target of therapy, we were 
also interested to know whether CD34+/CD38− stem 
cells in ALL express Hsp32. In these experiments, we 
were able to show that highly enriched (sorted) CD34+/
CD38− ALL stem cells as well as CD34+/CD38+ progenitor 
cells express Hsp32 mRNA in patients with Ph+ ALL and 
patients with Ph− ALL (Figure 1D). 
BCR/ABL1-targeting drugs down regulate 
expression of Hsp32 in ALL cells
We have recently shown that expression of Hsp32 in 
CML cells is triggered by BCR/ABL1 [28,29]. Therefore, 
we were interested to learn whether BCR/ABL1-targeting 
drugs would alter expression of Hsp32 in Ph+ ALL cells. 
As assessed by qPCR, imatinib was found to down 
regulate expression of Hsp32 mRNA in the Ph+ ALL 
cell lines TOM-1 and NALM-1 (Figure 2A). In contrast, 
imatinib did not suppress expression of Hsp32 mRNA 
in the Ph− ALL cell lines tested (Figure 2A). These data 
suggest that BCR/ABL1 is involved in the expression of 
Hsp32 in Ph+ ALL, whereas in Ph− ALL, other mechanisms 
contribute to Hsp32 expression.
Depletion of Hsp32 leads to apoptosis and growth 
arrest in ALL cells
Hsp32 is a well-known survival factor that 
counteracts apoptosis in various cell types. To investigate 
the functional role of Hsp32 in ALL cells, expression of 
Hsp32 was specifically silenced by siRNA in the Ph+ ALL 
cell lines TOM-1 and NALM-1 and in the Ph− cell line 
Raji. The siRNA-induced knockdown of Hsp32 was found 
to be associated with a significant decrease in cell viability 
due to an increase of apoptotic cells (Figure 2B). A control 
siRNA (against Luc) showed no substantial effect on 
expression of Hsp32 and no effect on survival (apoptosis) 
of ALL cells (Figure 2B). As expected, the siRNA-induced 
knock-down of Hsp32 also induced growth arrest in the 
ALL cell lines tested (Figure 2B). 
Effects of pharmacologic inhibitors of Hsp32 on 
growth of ALL cell lines
To evaluate the role of Hsp32 as a potential 
therapeutic target in ALL cells, two water-soluble 
pharmacologic inhibitors were applied, SMA-ZnPP 
and PEG-ZnPP. As assessed by 3H-thymidine uptake, 
both Hsp32-targeting drugs were found to inhibit the 
proliferation of Ph+ and Ph− ALL cells (primary cells and 
cell lines) after 48 hours of incubation (Figure 2C and 
Figure 2D). The effects of both drugs on growth of ALL 
cells were dose-dependent, with comparable IC50 values 
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#1 f 33 c-ALL - 52.1 12.6 139 46,XX + + 20 µM 20 µM
#2 m 73 pre-B-ALL p210 140 10 19 47,XY,t(9;22)(q34;q11)+20 + + 5 µM 20 µM
#3 m 39 c-ALL p190 61.6 9.4 56 46,XY, t(9;22) (q34;q11) + + 1 µM 20 µM
#4 f 20 pre-B-ALL - 14.6 8.7 29 46,XX, complex + + 5 µM n.t.
#5 f 35 c-ALL p190 24.72 13.1 177 53,XX,t(9;22) (q34;q11, complex + + 1 µM 5 µM
#6 f 65 pre-B-ALL - 170 9.1 111 46,XX,t(2;5),t(4;11) + + n.t. n.t.
#7 f 21 c-ALL - 568 7.1 75 46,XX + + 1 µM 5 µM
#8 m 17 pre-T-ALL - 4.2 8.1 16 47,XY, del(13), +19 + + n.t. n.t.
#9 f 56 pre-B-ALL p190 2.3 7.4 86 46,XX, t(9;22) (q34;q11) + + n.t. n.t.
#10 f 64 biphenotypic AL p210 53.2 10.5 91 46,XX, t(9;22) (q34;q11) + + n.t n.t.
#11 f 71 T-ALL - 9.3 5.5 30 46,XX, complex + + 10 µM 0.5 µM
#12 m 60 pre-B-ALL - 37.6 18.5 77 46,XY, t(1;19),del(13) + + 5 µM 10 µM
#13 f 55 c-ALL p190 71.29 13.7 73 46, XX, t(9;22) (q34;q11) + + n.t. n.t.
#14 m 17 pre-B-ALL - 19.74 3.9 114 46,XY,del(9)(q21), idem+8 + + n.t. n.t.




+ + 0.5 µM 0.5 µM
#16 f 45 T-ALL - 92.02 9 15 46,XX + + n.t n.t.
#17 f 35 c-ALL* p210* 32.97 9.7 172 46,XX, t(9;22) (q34;q11) + + 5 µM 5 µM
#18 f 35 pre-B-ALL - 155.26 8.6 52 46,XX,t(19;11), complex + + n.t. n.t.
#19 f 37 pre-B-ALL p190 4.4 7.6 3 46,XX, t(9;22) (q34;q11) + + n.t. n.t.





+ + n.t. n.t.
#21 f 57 pre-B-ALL - 10.31 9.7 141 46,XX n.t n.t. 1 µM 5 µM
#22 m 21 biphenotypic AL - 31.73 11.3 75 46,XY, t(2;14) n.t. n.t. 1 µM 20 µM




n.t n.t. 10 µM 1 µM
#24 f 22 relapsedpre-B-ALL - 17.65 9.6 24
47,XX, t(14;14), 
complex + + 1 µM n.t.
#25 m 72 c-ALL p210 106.01 10.1 73 46, XY, t(9;22) (q34;q11) n.t. + n.t. n.t.
#26 f 32 pre-B-ALL - 117.88 8.9 69 46,XX,del(9)(p13) n.t. + n.t. n.t.
*In these patients, imatinib resistance developed during the course of disease; in patient #23, a BCR/ABL1 T315I mutation was detected. For evaluation 
of proliferation, ALL cells were cultured in control medium or in various concentrations of Hsp32-inhibitors for 48 hours. Thereafter, 3H-thymidine-
uptake was measured and IC50 values (µM) determined. Abbreviations: WBC, white blood cell count; Hb, hemoglobin; Plt, platelet count; ICC, 
immunocytochemistry; n.t., not tested; p210, BCR/ABL1 major breakpoint; p190, BCR/ABL1 minor breakpoint.
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Figure 1:Expression of Hsp32 in ALL cells. A: Primary ALL cells (left panel) and cell lines (right panel) were subjected to RNA 
isolation and RT-PCR using primers specific for Hsp32 and human ABL (control) as described in the text. Before RNA was isolated, cells 
were cultured in control medium (Co) or in medium containing 10 µM hemin (He) at 37°C for 8 hours. Expression of Hsp32 mRNA and 
ABL mRNA was determined by qPCR. The left panel shows data obtained with primary ALL cells (7 Ph+ donors and 10 Ph─ donors) and 
the right panel shows data obtained with Ph+ and Ph─ cell lines (Ph+: BV-173, NALM-1, TOM-1, Z-119, Ph-: Raji, Ramos, REH, BL-41). 
Hsp32 mRNA levels are expressed as percentage of ABL mRNA levels and represent the mean±S.D. from all donors or cell lines. Asterisk: 
p<0.05. B: Immunocytochemical detection of the Hsp32 protein in primary ALL cells (left panel, Ph+ patients #10 and #17; and Ph- patient 
#14 from Table 1) and cell lines (right panel) after incubation in control medium or hemin (10 µM) at 37°C for 8 hours. After incubation, 
cells were spun on cytospin slides and stained with an antibody against Hsp32 as described in the text. Images were taken using an Olympus 
DP21 camera connected to an Olympus BX50F4 microscope equipped with 100x/1.35 UPlan-Apo objective lense (Olympus, Hamburg, 
Germany). Figures were prepared using Adobe Photoshop CS2 software version 9.0 (Adobe Systems, San Jose, CA) and processed with 
PowerPoint software (Microsoft, Redmond, WA). C: Western blot analysis of expression of Hsp32 in Ph+ cell line Z-119 (left) and Ph─ 
cell line BL-41 (right). Cells were incubated with control medium (Co) or hemin (10 µM) (He) at 37°C for 8 hours. Then, cells were lysed 
and lysates subjected to Western blot analysis using an antibody against Hsp32 and an antibody against ß-actin as described in the text. 
D: Expression of HO-1 mRNA in highly enriched (sorted) CD34+/CD38- stem cells and CD34+/CD38+ progenitor cells obtained from 3 
patients with Ph- ALL (left side) and 3 patients with Ph+ ALL (p210 right side)  as determined by qPCR. Cells were subjected to RNA 
isolation, cDNA synthesis and qPCR using primers specific for HO-1 and ABL. Results show HO-1 mRNA levels as percent of ABL mRNA 
levels, and represent the mean±S.D. of 3 independent experiments (3 patients).
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Figure2:Targeting of Hsp32 in ALL cells and functional consequences. A: Effects of BCR/ABL1-targeting drugs on expression 
of Hsp32 mRNA in leukemic cells. The Ph+ ALL cell lines NALM-1 and TOM-1 and the Ph─ cell line Ramos and BL-41 were incubated 
in control medium or imatinib (1 µM) at 37°C for 24 hours. Then, cells were recovered and subjected to RNA isolation and real time PCR 
using primers specific for Hsp32 and ABL. Results show Hsp32 mRNA expression levels relative to ABL mRNA levels. B: siRNA-induced 
Hsp32 knockdown in ALL cells is followed by apoptosis. The ALL cell lines NALM-1, TOM-1 and Raji were kept in control medium 
(Co) or were transfected with a control siRNA against luciferase (Luc siRNA) or siRNA against Hsp32 (200 nM each) as described in the 
text. After 48 hours, the percentage of apoptotic cells was determined by light microscopy (upper panel). Results represent the mean±S.D. 
from three independent experiments. Lower panel: 3H-thymidine uptake was measured after transfection with control siRNA or siRNA 
against Hsp32. Results show the percent of 3H-thymidine uptake compared to control and are expressed as mean±S.D. of triplicates. C,D: 
PEG-ZnPP and SMA-ZnPP inhibit growth of ALL cells. Primary leukemic cells (C) were obtained from patient #17 at two different time 
points, i.e. when cells were imatinib-sensitive and later when the patient developed imatinib-resistance, and from patient #21 with Ph- ALL. 
Cells were incubated in control medium (Co), various concentrations of PEG-ZnPP or various concentrations of SMA-ZnPP (as indicated) 
at 37°C for 48 hours. In patient #17, cells were also incubated with imatinib (0.05-0.5 µM) for 48 hours. After incubation, 3H-thymidine 
uptake was measured. Results show the percentage of 3H-thymidine uptake compared to control and are expressed as mean±S.D. of 
triplicates. Figure 2D shows result obtained with the Ph+ ALL cell lines BV-173 and TOM-1 and the Ph─ cell lines REH and Raji. Results 
show the percentage of 3H-thymidine uptake compared to control and are expressed as mean±S.D. of three independent experiments. 
Asterisk indicates p<0.05.
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(Tables 1 and 2).
Hsp32-targeting drugs suppress the growth 
of leukemic cells from patients with imatinib-
resistant ALL
In a substantial number of patients with ALL, 
leukemic cells develop resistance to imatinib. We were 
therefore interested to know whether Hsp32-targeting 
drugs can suppress the growth of leukemic cells from 
patients with imatinib-resistant Ph+ ALL. In these 
experiments, SMA-ZnPP and PEG-ZnPP were found to 
inhibit growth of primary, imatinib-resistant leukemic 
cells in a dose-dependent manner in all patients examined 
(Figure 2C, Table 1), including one patient with lymphoid 
blast phase exhibiting BCR/ABL T315I (Table 1).
The growth-inhibitory effects of PEG-ZnPP and 
SMA-ZnPP on ALL cells are associated with 
induction of apoptosis
Hsp32 has been described as a survival factor 
counteracting apoptosis in various neoplastic cells. We 
next investigated whether the growth-inhibitory effects 
of Hsp32 inhibitors (SMA-ZnPP and PEG-ZnPP) are 
associated with induction of apoptosis in ALL cells. We 
found that both drugs induce apoptosis in primary ALL 
cells and in the ALL cell lines tested (Figure 3 and Table 
2). The apoptosis-producing effects of SMA-ZnPP and 
PEG-ZnPP on ALL cells were demonstrable by light 
microscopy (Figure 3A and 3B) as well as in a Tunel assay 
(Figure 3C). Furthermore, we were able to show by flow 
cytometry that SMA-ZnPP induces activation of caspase-3 
in ALL cells (Figure 3D). In normal bone marrow cells, 
neither SMA-ZnPP nor PEG-ZnPP were found to induce 
apoptosis over the dose-range tested (1-40 µM) confirming 
previous data [29].
Hsp32-targeting drugs synergize with BCR/
ABL1-targeting drugs (imatinib, nilotinib) 
and with bendamustine in producing growth 
inhibition in ALL cells
Next, we examined cooperative drug effects on 
growth and survival (apoptosis) of ALL cells. We found 
that Hsp32-targeting drugs synergize with BCR/ABL1 
TKI and with bendamustin in inducing growth inhibition 
and apoptosis in ALL cells (Figure 4A-C). To further 
validate Hsp32 as a potential drug-partner of TKI in ALL 
cells, we applied siRNA against Hsp32 and measured 
the proliferation of ALL cells as well as the response to 
imatinib. In these experiments, suboptimal concentrations 
of imatinib were applied. As shown in Figure 4D, addition 
of Hsp32-specific siRNA was found to potentiate the 
effects of imatinib on both ALL cell lines examined, 
TOM-1 and NALM-1. 
Table 2: Characterization of cell lines and response to SMA-ZnPP, PEG-ZnPP, and other drugs



















BV-173 B-ALL p210 0.1 µM + + 1-5 µM 1-5 µM 5-10 µM 5 µM
NALM-1 CML, lymphoid BP p210 0.4µM + + 1-5 µM 1-5µM 5 µM n.t.
TOM-1 B-ALL p190 0.3 µM + + 1-5 µM 1-5 µM 10 µM 15-20 µM
Z-119 B-ALL p190 0.2 µM + + 1 µM 1-5 µM 5 µM 10 µM
RAJI Burkitt lymphoma - >1 µM + + 5 µM 5 µM 5-10 µM 20 µM
RAMOS Burkitt lymphoma - >1 µM + + 5 µM 5 µM 10 µM 20 µM
REH B-ALL - >1 µM + + 5 µM 10 µM 5-10 µM 20 µM
BL-41 Burkitt lymphoma - >1 µM + + 1-5 µM 1-5 µM 1-5 µM 15 µM
CML, chronic myeloid leukemia; BP, blast phase; ALL, acute lymphoblastic leukemia; p210, BCR/ABL1 major breakpoint; p190, BCR/ABL1 minor 
breakpoint. Immunocytochemical (ICC) analysis of Hsp32 (HO-1) and qPCR analysis of Hsp32 (HO-1) mRNA expression were performed as described in 
the text. Cell lines were cultured in control medium or in various concentrations of the Hsp32 (HO-1) inhibitors SMA-ZnPP or PEG-ZnPP, or in the presence 
of various concentrations of the BCR/ABL1 kinase blockers imatinib or nilotinib for 48 hours. Thereafter, proliferation was measured by 3H-thymidine 
incorporation assay. IC50 values (µM) represent the mean from at least 3 independent experiments. Apoptosis was determined by light microscopy; EC50 
values (µM) represent the mean from at least 3 independent experiments. n.t., not tested.
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Figure3:Hsp32-targeting drugs induce apoptosis in ALL cells. A: Primary leukemic cells obtained from patient #17 with Ph+ 
ALL (imatinib-sensitive phase) and patient #18 with Ph− ALL were incubated in control medium (Co) or medium containing increasing 
concentrations of either PEG-ZnPP or SMA-ZnPP at 37°C for 24 hours. Thereafter, the numbers of apoptotic cells were determined by 
light microscopy (upper panels) and AnnexinV staining and flow cytometry (lower panels). B: The lymphoid cells lines BV-173, TOM-1, 
REH and BL-41 were incubated in control medium (Co) or increasing concentrations of either SMA-ZnPP (left panel) or PEG-ZnPP (right 
panel) at 37°C for 48 hours. Then, the number (percentage) of apoptotic cells was determined by light microscopy. Asterisk (*): p<0.05. C: 
A Tunel assay was performed with Z-119 cells after incubation in control medium (Control), PEG-ZnPP (5 µM) or SMA-ZnPP (10 µM) at 
37°C for 48 hours. After incubation, cells were analyzed under a fluorescence microscope and photographs taken as described in the text. 
Original magnification x 40. D: Flow cytometric evaluation of expression of active caspase 3 in two Ph+ALL cell lines (BV-173, TOM-1) 
and two Ph−ALL cell lines (REH, BL-41) after incubation in control medium or medium containing 10 µM of SMA-ZnPP. Results represent 
the mean±S.D. of three independent experiments.
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Figure4:Hsp32-targeting drugs synergize with 
bendamustine and with BCR/ABL1-targeting drugs 
in producing growth inhibition and apoptosis in ALL 
cells. A: The Ph+ ALL cell line TOM-1 was incubated in control 
medium or various concentrations of imatinib and SMA-ZnPP or 
a combination of both drugs for 48h. Thereafter, 3H-thymidine 
incorporation was measured. Results represent the mean±S.D. 
of triplicate experiments and are expressed in percent of 
control. B,C: The Ph+ ALL cell line Z-119 was incubated with 
control medium or various concentrations of imatinib, nilotinib, 
PEG-ZnPP, or SMA-ZnPP, alone or with a combination (with 
fixed drug ratio) of these drugs as indicated for 24 hours. 
Thereafter, the percentages of apoptotic cells were determined 
by light microscopy. Results represent the mean±S.D. of three 
independent experiments. D: The ALL cell lines NALM-1 and 
TOM-1 were left untransfected (Co) or were transfected with a 
control siRNA against luciferase (Luc siRNA) or siRNA against 
Hsp32 (200 nM each) as described in the text. 48 hours after 
transfection, cells were incubated in control medium or various 
concentrations of imatinib for 48h. Thereafter, 3H-thymidine 
incorporation was measured. Results represent the mean±S.D. 
of triplicate experiments and are expressed as percent of control.
Oncotarget1207www.impactjournals.com/oncotarget
DISCUSSION
Recent data suggest that Hsp32 is an important 
survival factor and potential target in various malignant 
cells [22-27]. We have recently shown that CML cells 
constitutively express Hsp32 and that the disease-related 
oncoprotein BCR/ABL1 promotes expression of Hsp32 
in Ba/F3 cells [28,29]. In the present study, we show 
that Hsp32 is also expressed and serves as an essential 
´survival-molecule´ in Ph+ and Ph− ALL cells. Our data 
also show that Hsp32-targeting drugs induce apoptosis and 
growth arrest in ALL cells and synergize with BCR/ABL1 
TKI and with bendamustin in producing growth inhibition 
in imatinib-sensitive and imatinib-resistant ALL cells. 
Together, these data suggest that Hsp32 is a potential new 
target in ALL.
Expression of Hsp32 in ALL cells was 
demonstrable by qPCR and Western blotting as well as 
by immunocytochemistry. Interestingly, both the Ph+ ALL 
cells and Ph− ALL cells were found to express Hsp32, 
suggesting that apart from BCR/ABL1, other mechanisms 
and molecules may also contribute to expression of this 
´survival-molecule´ in leukemic cells. Baseline levels of 
Hsp32 were comparable in Ph+ and Ph− ALL cells and 
were upregulated by hemin.
In Ph+ CML, BCR/ABL1 promotes the expression 
of Hsp32 in leukemic cells [28]. To explore the potential 
role of this pathway in expression of Hsp32 in Ph+ ALL 
cells, we treated these cells with BCR/ABL1-targeting 
drugs. We found that BCR/ABL1 TKI downregulate the 
expression of Hsp32 mRNA in Ph+ ALL cells. These data 
suggest that BCR/ABL1 may contribute to expression 
of Hsp32 in Ph+ ALL cells. However, as mentioned, 
Hsp32 was also detectable in Ph− ALL cells. From these 
data, we hypothesize that expression of Hsp32 can also 
be triggered by other pathways in ALL cells. Indeed it 
has been described that several different oncoproteins, 
including JAK2 V617F, KIT D816V or RAS G12V induce 
expression of Hsp32/HO-1 in neoplastic cells [30]. The 
exact nature of additional HO-1-promoting oncogenic 
lesions in ALL cells remains at present unknown. 
Alternatively, Hsp32 expression in ALL cells may 
also be regulated by external factors. In this regard it is 
noteworthy that Hsp32 is an established “stress-induced” 
survival factor in various physiologic cells and that several 
different stimuli, including chemotherapy agents, can 
induce expression of Hsp32/HO-1 in malignant cells [30]. 
To demonstrate that Hsp32 serves as a survival 
factor in ALL cells, we performed experiments using 
ALL cell lines and siRNA against Hsp32. The observation 
that the siRNA-induced knock-down is associated with 
apoptosis and growth arrest in these cells suggests that 
Hsp32 serves as an important survival factor in ALL cells 
and thus may represent a potential therapeutic target.
In the past few years, two water-soluble 
pharmacologic inhibitors of Hsp32, SMA-ZnPP and PEG-
ZnPP, have been developed and tested in experimental 
solid tumors [22-27]. In the current study these two 
inhibitors were applied to target Hsp32 in ALL cells. Both 
inhibitors were found to downregulate growth and survival 
in primary (Ph+ and Ph−) ALL cells as well as in all ALL 
cell lines tested. By contrast, the Hsp32 inhibitors showed 
no major effects on viability of normal cells [28]. All in 
all, these data suggest that pharmacologic targeting of 
Hsp32 in ALL cells may result in their selective apoptosis 
and growth arrest.
A major clinical challenge in the treatment of ALL is 
resistance to imatinib and other BCR/ABL1 TKI [10-13]. 
Therefore, a number of novel agents and pharmacologic 
approaches are currently under investigation, with the 
aim to overcome drug-resistance. In the present study, 
we found that PEG-ZnPP and SMA-ZnPP induce growth 
arrest and apoptosis not only in imatinib-sensitive ALL 
cells but also in imatinib-resistant cells, which may be 
of clinical interest. These data are also in line with our 
previous observations that Hsp32 inhibitors block the 
growth of imatinib-resistant CML cells as well as Ba/
F3 cells expressing various imatinib-resistant mutants 
of BCR/ABL1, including the T315I mutant that renders 
BCR/ABL1 resistant against all currently available BCR/
ABL1 TKI [29]. In the present study, we examined one 
CML patient in lymphoid blast phase exhibiting the T315I 
mutant. As expected, both PEG-ZnPP and SMA-ZnPP 
were found to suppress the growth of leukemic cells in this 
patient. Together, our data suggest that targeting of Hsp32 
may be an interesting approach to treat patients with drug-
resistant Ph+ ALL or lymphoid blast phase of CML.
An attractive strategy to overcome drug resistance 
in leukemias is to combine various targeted drugs with 
each other or with conventional drugs. The data of our 
study show that Hsp32-targeting drugs synergize with 
imatinib and with nilotinib as well as with bendamustine 
in producing growth inhibition in Ph+ and Ph− ALL cells. 
These synergistic drug effects were seen in imatinib-
sensitive as well as in imatinib-resistant ALL cells, 
supporting the notion that Hsp32 may be an attractive 
new therapeutic target in this disease. This hypothesis was 
further supported by the observation that siRNA against 
HO-1 substantially augments the growth-inhibitory effects 
of imatinib on ALL cells.   
In summary, our data show that Hsp32 is an 
important survival factor and potential new target in 
leukemic cells in Ph+ and Ph− ALL, including patients 
with TKI-resistant disease. Clinical studies are now 
warranted to show whether targeting of Hsp32 alone or in 
combination with BCR/ABL1 TKI or other inhibitors, can 




Pegylated zinc protoporphyrin (PEG-ZnPP) and 
ZnPP encapsulated in the micelle of styrene maleic acid 
(SMA-ZnPP), were produced as described previously 
[31-33]. Imatinib and nilotinib (AMN107) were kindly 
provided by Dr.E.Buchdunger and Dr.P.W.Manley 
(Novartis Pharma AG, Basel, Switzerland). Bendamustine 
was kindly provided by Dr.D.Guggi (Mundipharma, 
Vienna, Austria). RPMI 1640 medium and fetal calf serum 
(FCS) were purchased from PAA laboratories (Pasching, 
Austria), hemin and bovine serum albumin (BSA) from 
Sigma-Aldrich (St. Louis, Mo), and lipofectin from 
Invitrogen (Carlsbad, CA).
Primary ALL cells and cell lines
For in vitro culture experiments, primary leukemic 
cells were obtained from 11 patients with Ph+ ALL, 15 
with Ph− ALL, 4 with T-ALL, 2 with biphenotypic acute 
leukemia, and one with a lymphoid blast phase of CML 
with BCR/ABL1 T315I. For polymerase chain reaction 
(PCR) analysis, frozen samples from 10 patients with Ph+ 
ALL and 10 with Ph− ALL were used. In 8 patients (5 with 
Ph+ ALL and 3 with Ph- ALL), CD34+/CD38− cells and 
CD34+/CD38+ cells were purified by cell sorting (purity 
>98%) as described [34]. The patients´ characteristics are 
shown in Table 1. Written informed consent was obtained 
in each case. The study was approved by the Ethics 
Committee of the Medical University of Vienna, Austria. 
The following Ph+ ALL cell lines were used: Z-119, BV-
173, TOM-1, and NALM-1. In addition, a number of Ph− 
lymphatic cell lines were used: Raji, Ramos, REH, and 
BL-41. Z-119 cells were kindly provided to J.V.M. by 
Dr. Zeev Estrov (MD Anderson Cancer Centre, Houston, 
Texas, USA). All other cell lines were purchased from 
the Leibnitz Institute DSMZ-German Collection of 
Microorganisms and Cell Cultures (Braunschweig, 
Germany). The identity of the cell lines was reconfirmed 
by DNA sequencing and DNA profiling (by nonaplex 
PCR) and by studying the presence or absence of BCR/
ABL1. Cell lines were cultured in RPMI 1640 medium and 
20% heat-inactivated FCS at 37°C and 5% CO2. Table 2 
shows a summary of characteristics of cell lines tested in 
this study.
Real time PCR
RNA was isolated from primary ALL cells and 
cell lines using the RNeasy MinEluteCleanupKit 
(Qiagen, Hiden, Germany). cDNA was synthesized using 
Moloney murine leukemia virus reverse transcriptase 
(Invitrogen), random primers, First Strand buffer, 
dNTPs (100 mM), and RNasin (all from Invitrogen) 
according to the manufacturer`s instructions. PCR 
was performed using primers specific for Hsp32 




(forward), and 5´-GCCTA AGACCCGGAGCTTTTCA-3´ 
(reverse). mRNA levels were quantified on a 7900HT 
Fast Real-Time PCR System (Applied Biosystem, Foster 
City, CA) using iTAq SYBR Green Supermix with ROX 
(Bio-Rad, Hercules, CA). Hsp32 mRNA expression levels 
were normalized to ABL mRNA levels. Calculations were 
based on standard curves established for Hsp32 and ABL 
mRNA expression. Hsp32 mRNA levels were expressed 
as percentage of ABL mRNA.
Immunocytochemistry
Immunocytochemistry was performed on cytospin-
slides prepared with primary neoplastic cells, sorted ALL 
stem cells, and cell lines. A polyclonal rabbit anti- HO-1 
(anti-Hsp32) antibody (Stressgen, Ann Arbor, MI; dilution 
1:100) and a biotinylated goat-anti-rabbit IgG (Biocare, 
San Diego, CA) were applied essentially as described 
[28,35]. Slides were incubated with the primary antibody 
overnight, washed, and were then incubated with second-
step antibody for 30 minutes. Streptavidin-alkaline-
phosphatase complex (Biocare) was used as chromogen. 
Antibody reactivity was made visible using Neofuchsin 
(Nichirei, Tokyo, Japan). Slides were counterstained in 
Mayer`s hemalaun. In control experiments, the primary 
antibody was preincubated with control buffer or a Hsp32-
specific blocking peptide (Stressgen) before being applied.
Western blotting
The Ph+ cell line Z-119 and the Ph− cell line BL-41 
were incubated with hemin (10 µM, 37°C, 8 hours) before 
being analyzed. Western blotting was performed using a 
polyclonal rabbit anti-Hsp32 antibody (Stressgen) and an 
anti--actin antibody (Santa Cruz), as described [28,35]. 
Antibody reactivity was made visible by donkey anti-
rabbit IgG antibody and Lumigen PS-3 detection reagent 
(both from GE Healthcare, Buckinghamshire, UK).
Design and application of siRNA against Hsp32
siRNA against Hsp32 
(5’-AAGCUUUCUGGUGGCGACAGUdTdT-3’) 
as well as a control siRNA against luciferase 
(5’-CUUACGCUGAGUACUUCG AdTdT-3’) were 
Oncotarget1209www.impactjournals.com/oncotarget
synthesized by Dharmacon Research (Lafayette, CO). 
The siRNA (200 nM) was transfected into NALM-1, Raji 
and TOM-1, using lipofectin (Invitrogen) as reported [35]. 
Proliferation of transfected and control cells was analyzed 
by determining 3H-thyimidine uptake. In addition, the 
percentage of apoptotic cells was determined by Wright-
Giemsa staining after 48 hours. In a separate set of 
experiments, siRNA-transfected NALM-1 and TOM-1 
cells were incubated in various concentrations of imatinib 
(10-24 nM) at 37°C for 48 hours. Then, cells were 
examined for proliferation by measuring 3H-thyimidine 
uptake.
Proliferation assay
To examine anti-proliferative effects of PEG-ZnPP 
and SMA-ZnPP, Ph+ and Ph− ALL cell lines and primary 
ALL cells were cultured in 96-well microtiter plates (5 x 
104 cells per well) in the absence or presence of various 
concentrations of PEG-ZnPP or SMA-ZnPP for 48 hours, 
followed by addition of 3H-thymidine (0.5 µCi per well) 
for 16 hours. Cells were harvested on filter membranes 
(Packard Bioscience, Meriden, CT) in a Filtermate 96 
harvester (Packard Bioscience). Filters were air-dried, and 
the bound radioactivity was measured in a -counter (Top-
Count NXT, Packard Bioscience). All experiments were 
performed in triplicate. In a separate set of experiments, 
cell lines were cultured in the presence of various drug 
combinations at a fixed concentration-ratio for each 




The effects of SMA-ZnPP and PEG-ZnPP on cell 
viability (apoptosis) were analyzed by morphologic 
examination. Cells were incubated with various 
concentrations of SMA-ZnPP or PEG-ZnPP (1-20 µM) 
at 37°C for 48 hours. The percentage of apoptotic cells 
was quantified on Wright-Giemsa-stained cytospin slides 
[36]. In select experiments, Hsp32-targeting drugs were 
applied in combination with TKI (imatinib or nilotinib) 
or bendamustine. To confirm apoptosis in drug-exposed 
cells, combined AnnexinV/propidium-iodide staining was 
performed using the apoptosis detection kit from Alexis 
Biochemicals (Lausen, Switzerland) as described [29]. 
Cells were analyzed by flow cytometry on a FACScan 
(Becton Dickinson, San Jose, CA). A Tunel assay was 
performed using the ´In situ cell death detection kit´ 
(Roche, Mannheim, Germany) as reported [35]. In brief, 
cells were incubated with 10 µM SMA-ZnPP, 5 µM PEG-
ZnPP, or control medium for 48 hours and then spun on 
cytospin slides, fixed in 4% paraformaldehyde, washed, 
and permeabilized in 0.1% Triton X-100 and 0.1 % sodium 
citrate. Then, cells were washed and incubated in terminal-
transferase reaction-solution for 60 minutes at 37°C. Cells 
were analyzed under a Carl Zeiss Imager. A1 microscope 
(Carl Zeiss, Jena, Germany). For caspase 3 detection, 
cell lines were incubated in control medium or in various 
concentrations of SMA-ZnPP (5-20 µM) at 37°C for 
48 hours. Then, cells were fixed in 2% formaldehyde 
(room temperature, 10 minutes), permeabilized in 100% 
methanol at -20°C (15 minutes), washed in PBS plus BSA 
(0.1%), and then stained with the FITC-conjugated mAb 
C92-605 (Becton Dickinson Biosciences) directed against 
active caspase 3 for 1 hour. Thereafter, cells were analyzed 
by flow cytometry on a FACSCalibur (Becton Dickinson 
Biosciences).
Statistical analysis
The paired Student´s t test was applied in growth 
inhibition-experiments. Results were considered to be 
significantly different, when the p-value was <0.05. 
Drug combination effects (additive versus synergistic) 
were determined by calculating the combination index 
(CI) values using Calcusyn software (Calcusyn; Biosoft, 
Ferguson, MO) [37]. A CI value of 1 indicates additive 
effects and a CI below 1 indicates synergistic drug 
interactions.
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